INO - Inovio Pharmaceuticals Inc Stock Price, Fair Value and News

12.00USD-0.79 (-6.18%)Market Closed

Market Summary

USD12.00-0.79

Market Closed

-6.18%

INO Stock Price

View Fullscreen

INO RSI Chart

INO Valuation

Market Cap

310.9M

Price/Earnings (Trailing)

-2.49

Price/Sales (Trailing)

63.89

EV/EBITDA

-2.22

Price/Free Cashflow

-2.67

INO Price/Sales (Trailing)

INO Profitability

EBT Margin

-2776.48%

Return on Equity

-132.32%

Return on Assets

-96.79%

Free Cashflow Yield

-37.48%

INO Fundamentals

INO Revenue

Revenue (TTM)

4.9M

Rev. Growth (Yr)

-17.66%

Rev. Growth (Qtr)

-73.57%

INO Earnings

Earnings (TTM)

-125.0M

Earnings Growth (Yr)

24.97%

Earnings Growth (Qtr)

-21.98%

Breaking Down INO Revenue

Last 7 days

12.7%

Last 30 days

8.4%

Last 90 days

51.3%

Trailing 12 Months

53.9%

How does INO drawdown profile look like?

INO Financial Health

Current Ratio

4.77

INO Investor Care

Shares Dilution (1Y)

18.34%

Diluted EPS (TTM)

-5.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	12.3M	13.7M	4.9M	4.9M
2022	2.7M	2.7M	11.5M	10.8M
2021	8.3M	8.2M	7.6M	2.8M
2020	2.6M	3.5M	3.6M	8.9M
2019	31.8M	7.5M	6.3M	4.1M
2018	39.3M	36.4M	33.4M	30.5M
2017	37.6M	51.8M	41.9M	42.2M
2016	43.5M	44.4M	32.8M	35.4M
2015	13.3M	14.8M	37.1M	40.6M
2014	14.4M	17.4M	9.7M	10.5M
2013	3.9M	4.2M	12.9M	13.5M
2012	8.4M	6.4M	4.6M	4.1M
2011	7.9M	9.2M	10.5M	9.8M
2010	0	8.1M	7.1M	6.1M
2009	0	0	0	9.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Inovio Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 26, 2024	humeau laurent	sold (taxes)	-19,184	8.16	-2,351	chief scientific officer
Feb 26, 2024	shea jacqueline elizabeth	sold (taxes)	-30,420	8.16	-3,728	chief executive officer
Feb 26, 2024	kies peter	sold (taxes)	-28,282	8.16	-3,466	cfo
Feb 26, 2024	kies peter	acquired	-	-	5,875	cfo
Feb 26, 2024	weiner david b.	acquired	-	-	2,916	-
Feb 26, 2024	humeau laurent	acquired	-	-	5,734	chief scientific officer
Feb 26, 2024	shea jacqueline elizabeth	acquired	-	-	7,731	chief executive officer
Jun 30, 2023	sumner michael john	acquired	-	-	35,000	chief medical officer
Jun 05, 2023	zoth lota s.	sold	-3,192	0.56	-5,700	-
May 16, 2023	zoth lota s.	acquired	-	-	19,000	-

Which funds bought or sold INO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Clear Point Advisors Inc.	new	-	430	430	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	442,147	442,147	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-235,523	-	-%
May 16, 2024	Clear Point Advisors Inc.	sold off	-100	-191	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-10,001	-	-%
May 15, 2024	Tudor Investment Corp Et Al	sold off	-100	-68,758	-	-%
May 15, 2024	Mariner, LLC	sold off	-100	-39,348	-	-%
May 15, 2024	Squarepoint Ops LLC	new	-	301,487	301,487	-%
May 15, 2024	STATE STREET CORP	new	-	1,230,890	1,230,890	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	721,524	721,524	-%

Are Funds Buying or Selling INO?

Are funds buying INO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INO

No. of Funds

Unveiling Inovio Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 26, 2024	deep track capital, lp	9.99%	2,593,822	SC 13G
Feb 13, 2024	vanguard group inc	7.24%	19,766,042	SC 13G/A
Jan 22, 2024	state street corp	0.32%	871,047	SC 13G/A
Jul 10, 2023	state street corp	0.33%	877,447	SC 13G/A
Jul 07, 2023	blackrock inc.	2.3%	6,086,623	SC 13G/A
Feb 09, 2023	state street corp	12.61%	31,472,352	SC 13G/A
Feb 09, 2023	vanguard group inc	6.83%	17,042,500	SC 13G/A
Jan 24, 2023	blackrock inc.	9.3%	23,284,119	SC 13G/A
Apr 11, 2022	state street corp	10.49%	23,267,928	SC 13G/A
Feb 11, 2022	state street corp	6.32%	13,300,430	SC 13G/A

Recent SEC filings of Inovio Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading

Peers (Alternatives to Inovio Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Inovio Pharmaceuticals Inc News

Latest updates

Inovio Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	102,651	388,446	2,168,233	2,207,171	124,666	9,154,133	857,667	669,814	839,115	291,698	928,111	769,237	5,580,581	896,710	1,067,399	1,327,274	279,488	866,863	135,674	2,829,905
Operating Expenses	14.5%	31,484,969	27,496,391	35,941,458	37,267,068	44,067,121	56,070,821	44,911,177	104,921,721	71,932,069	106,347,454	60,244,852	83,474,759	52,925,612	34,920,019	36,565,618	33,448,085	26,559,542	30,700,541	24,818,650	28,336,367	31,364,917
S&GA Expenses	-100.0%	-	10,243,341	9,925,055	13,523,098	13,890,610	13,950,944	11,824,047	48,456,836	15,953,458	14,048,635	13,156,183	12,666,341	13,881,194	8,617,458	10,110,506	11,071,510	7,448,354	8,696,586	5,681,441	5,850,101	6,975,029
R&D Expenses	21.2%	20,913,790	17,253,050	15,503,032	23,743,970	30,176,511	42,119,877	33,087,130	56,464,885	55,978,611	92,298,819	47,088,669	70,808,418	39,044,418	26,302,561	26,455,112	22,376,575	19,111,188	22,003,955	19,137,209	22,486,266	24,389,888
EBITDA Margin	-0.1%	-27.01	-26.98	-32.81	-12.01	-19.18	-25.24	-28.21	-130	-117	-105	-28.19	-16.00	-	-	-	-	-	-	-	-	-
Interest Expenses	-37.0%	177,833	282,325	313,488	313,488	313,488	313,488	313,488	313,488	313,488	480,313	476,374	466,726	513,034	1,068,008	1,984,046	2,846,641	2,803,755	2,668,837	2,428,671	2,194,783	656,248
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-87,764	-	-106,771	-62,800
Earnings Before Taxes	100.0%	-	-25,003,638	-33,929,864	-35,534,533	-40,649,317	-54,463,139	-37,783,896	-108,497,311	-76,908,506	-106,947,580	-60,169,041	-82,139,958	-53,967,744	-22,415,201	20,931,010	-128,270,709	-33,135,404	-38,235,146	-23,536,452	-29,685,847	-29,351,667
EBT Margin	0%	-27.76	-27.76	-33.67	-12.34	-19.56	-25.69	-28.66	-132	-119	-107	-28.89	-16.83	-	-	-	-	-	-	-	-	-
Net Income	-22.0%	-30,500,000	-25,003,638	-33,929,864	-35,534,533	-40,649,317	-54,463,139	-37,783,896	-108,497,311	-79,073,719	-106,947,580	-60,169,041	-82,139,958	-54,402,131	-24,338,380	19,171,336	-129,172,466	-33,135,404	-37,662,038	-23,090,693	-29,387,226	-29,219,262
Net Income Margin	7.5%	-25.68	-27.76	-33.67	-12.34	-19.56	-25.89	-28.84	-133	-120	-107	-29.20	-17.34	-	-	-	-	-	-	-	-	-
Free Cashflow	-9.6%	-28,795,534	-26,275,785	-29,110,632	-32,338,571	-36,961,461	-36,505,141	-67,552,146	-51,245,185	-61,882,102	-38,534,821	-46,659,317	-78,667,141	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-24.5%	129	171	193	233	267	349	392	459	446	496	536	592	655	540	438	443	339	144	152	165	191
Current Assets	-27.1%	112	153	175	203	234	315	350	416	400	448	487	542	588	471	377	382	276	94.00	99.00	111	135
Cash Equivalents	37.0%	20.00	14.00	19.00	53.00	28.00	46.00	22.00	41.00	59.00	71.00	68.00	59.00	84.00	251	179	215	158	22.00	16.00	20.00	21.00
Net PPE	1.1%	5.00	5.00	6.00	6.00	7.00	8.00	16.00	16.00	17.00	17.00	18.00	18.00	11.00	11.00	11.00	11.00	12.00	13.00	14.00	14.00	15.00
Goodwill	-	-	-	-	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00	11.00
Liabilities	-35.3%	35.00	54.00	55.00	64.00	67.00	126	125	162	90.00	96.00	82.00	83.00	73.00	79.00	114	257	151	139	115	109	110
Current Liabilities	-45.0%	23.00	43.00	44.00	52.00	55.00	97.00	95.00	131	59.00	66.00	51.00	52.00	42.00	42.00	41.00	38.00	32.00	32.00	20.00	24.00	27.00
Long Term Debt	-	-	-	-	-	-	17.00	16.00	17.00	16.00	15.00	14.00	15.00	14.00	5.00	4.00	14.00	13.00	64.00	8.00	63.00	61.00
LT Debt, Current	-100.0%	-	17.00	16.00	17.00	16.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	17.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-19.5%	94.00	117	138	169	199	222	267	298	355	400	454	509	582	461	324	186	188	5.00	36.00	56.00	81.00
Retained Earnings	-1.9%	-1,653	-1,622	-1,600	-1,600	-1,500	-1,487	-1,433	-1,395	-1,287	-1,209	-1,102	-1,042	-960	-906	-881	-901	-772	-739	-702	-679	-649
Additional Paid-In Capital	0.4%	1,749	1,741	1,737	1,734	1,728	1,711	1,701	1,694	1,642	1,610	1,557	1,551	1,542	1,367	1,206	1,088	958	743	735	732	727
Shares Outstanding	2.5%	23.00	23.00	22.00	22.00	22.00	21.00	21.00	20.00	18.00	17.00	17.00	17.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	4.00	2.00	2.00	3.00	3.00
Float	-	-	-	-	120	-	-	-	426	-	-	-	1,900	-	-	-	4,200	-	-	-	280	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-9.5%	-28,759	-26,275	-29,110	-32,314	-36,664	-36,340	-67,465	-50,527	-61,882	-37,891	-46,490	-78,459	-52,867	-51,216	-74,158	-27,151	-25,452	-13,737	-27,733	-23,924	-32,454
Share Based Compensation	11.4%	2,525	2,266	2,079	2,918	3,809	3,274	3,234	8,336	7,711	5,474	5,620	5,646	9,596	3,825	4,158	3,662	4,002	2,034	2,080	3,355	3,433
Cashflow From Investing	127.6%	45,383	19,943	-5,493	53,907	19,000	54,001	44,557	-10,304	21,332	-6,493	55,958	50,306	-275,115	-3,716	39,115	-42,385	-51,808	10,435	8,270	21,588	-49,337
Cashflow From Financing	-718.2%	-11,364	1,838	699	2,883	-424	6,668	3,812	42,939	28,422	47,595	-440	3,441	160,903	126,939	-1,695	126,523	213,513	9,645	15,581	1,294	78,877

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($)

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenues:

Revenue from collaborative arrangements and other contracts

$ 0

$ 114,943

Operating expenses:

Research and development

20,913,790

30,176,511

General and administrative

10,571,179

13,890,610

Total operating expenses

31,484,969

44,067,121

Loss from operations

(31,484,969)

(43,952,178)

Other income (expense):

Interest income

1,500,290

2,207,171

Interest expense

(177,833)

(313,488)

(Loss) gain on investment in affiliated entity

(126,018)

616,639

Net unrealized gain on available-for-sale equity securities

500,877

3,218,215

Other expense, net

(682,218)

(2,425,676)

Net loss

$ (30,469,871)

$ (40,649,317)

Net loss per share

Basic (in dollars per share)

^[1]

$ (1.31)

$ (1.89)

Diluted (in dollars per share)

^[1]

$ (1.31)

$ (1.89)

Weighted average number of common shares outstanding

Basic (in shares)

^[1]

23,291,512

21,536,476

Diluted (in shares)

^[1]

23,291,512

21,536,476

[1]	Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.

INO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 19,601,829	$ 14,310,862
Short-term investments	86,013,044	130,982,913
Accounts receivable from affiliated entities	2,551,082	2,405,228
Prepaid expenses and other current assets	3,517,081	5,393,665
Prepaid expenses and other current assets from affiliated entities	0	20,432
Total current assets	111,683,036	153,113,100
Fixed assets, net	5,015,067	4,960,986
Investment in affiliated entity	2,654,269	2,780,287
Operating lease right-of-use assets	9,156,478	9,491,735
Other assets	605,315	605,315
Total assets	129,114,165	170,951,423
Current liabilities:
Accrued clinical trial expenses	3,022,486	2,365,382
Operating lease liability	2,155,540	2,406,522
Grant funding liability	0	87,489
Grant funding liability from affiliated entity	21,918	21,918
Convertible senior notes	0	16,770,654
Total current liabilities	23,400,945	42,570,228
Operating lease liability, net of current portion	11,271,257	11,032,066
Total liabilities	34,672,202	53,602,294
Stockholders’ equity:
Preferred stock	0	0
Common stock	23,370	22,792
Additional paid-in capital	1,748,529,814	1,740,954,074
Accumulated deficit	(1,653,435,007)	(1,622,965,136)
Accumulated other comprehensive loss	(676,214)	(662,601)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity	94,441,963	117,349,129
Total liabilities and stockholders’ equity	129,114,165	170,951,423
Nonrelated Party
Current liabilities:
Accounts payable and accrued expenses	16,675,922	19,847,744
Related Party
Current liabilities:
Accounts payable and accrued expenses	$ 1,525,079	$ 1,070,519

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

CEO	Dr. Jacqueline E. Shea Ph.D.
WEBSITE	inovio.com
INDUSTRY	Biotechnology
EMPLOYEES	135

Inovio Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Inovio Pharmaceuticals Inc? What does INO stand for in stocks?

INO is the stock ticker symbol of Inovio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inovio Pharmaceuticals Inc (INO)?

As of Fri May 17 2024, market cap of Inovio Pharmaceuticals Inc is 310.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INO stock?

You can check INO's fair value in chart for subscribers.

What is the fair value of INO stock?

You can check INO's fair value in chart for subscribers. The fair value of Inovio Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inovio Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inovio Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether INO is over valued or under valued. Whether Inovio Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Inovio Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INO.

What is Inovio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, INO's PE ratio (Price to Earnings) is -2.49 and Price to Sales (PS) ratio is 63.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Inovio Pharmaceuticals Inc's stock?

In the past 10 years, Inovio Pharmaceuticals Inc has provided -0.197 (multiply by 100 for percentage) rate of return.